Document is current

Article History

Received: 13 June 2025

Revised: 19 February 2026

Accepted: 4 March 2026

First Online: 28 March 2026

Competing interests

: The authors declare no competing interests. SRS Consultant (C): 4DMT, Abbvie, Alexion, Allergan Inc., Alnylam Pharmaceuticals, Amgen Inc., Apellis Pharmaceuticals, Inc., Astellas, Bayer Healthcare Pharmaceuticals, Biogen MA Inc., Boehringer Ingelheim, Carl Zeiss Meditec, Catalyst Pharmaceuticals Inc., Centervue Inc., GENENTECH, Gyroscope Therapeutics, Heidelberg Engineering, Hoffman La Roche, Ltd., Iveric Bio, Janssen Pharmaceuticals Inc., Nanoscope, Notal Vision Inc., Novartis Pharma AG, Optos Inc., Oxurion/Thrombogenics, Oyster Point Pharma, Regeneron Pharmaceuticals Inc., Samsung Bioepis, Topcon Medical Systems Inc. Recipient (R): Carl Zeiss Meditec, Heidelberg Engineering, Nidek Incorporated, Novartis Pharma AG, Topcon Medical Systems Inc. Financial Support (F): Carl Zeiss Meditec, Heidelberg Engineering, Optos Inc., Nidek, Topcon, Centervue.